MicroRNA-202-3p Regulates Scleroderma Fibrosis by Targeting Matrix Metalloproteinase 1
Overview
General Medicine
Pharmacology
Affiliations
The leading cause of death in systemic sclerosis (SSc) is the uncontrolled fibrosis in multiple organs. The exact mechanism of fibrosis is not fully clear. Our previous studies using miRNA array analysis indicated that miR-202-3p was increased in SSc lesion skin tissues. Bioinformatics analysis suggested matrix metallopeptidase (MMP) 1 is the target gene of miR-202-3p. Here we confirmed that miR-202-3p was upregulated, and the mRNA and protein expression of MMP1 were significantly decreased in SSc skin tissues and primary fibroblast compared with normal skin. MMP1 expression was inversely correlated with the expression of miR-202-3p. Overexpression of miR-202-3p markedly increased collagen disposition in skin primary fibroblasts, while inhibitor of miR-202-3p decreased it. Furthermore, we demonstrated that MMP1 was a target of miR-202-3p detected by luciferase reporter assay, and played an essential role as a mediator of the biological effects of miR-202-3p in SSc fibrosis. Taken together, these findings suggest that miR-202-3p may function as a novel pro-fibrotic miRNA in SSc by inhibition the expression of MMP1.
Chandrasegaran S, Sluka J, Shanley D bioRxiv. 2024; .
PMID: 39026713 PMC: 11257496. DOI: 10.1101/2024.07.04.602041.
Virus-Induced MicroRNA Modulation and Systemic Sclerosis Disease.
Soffritti I, DAccolti M, Bini F, Mazziga E, Di Luca D, Maccari C Biomedicines. 2024; 12(6).
PMID: 38927567 PMC: 11202132. DOI: 10.3390/biomedicines12061360.
MiR-202-3p inhibits the proliferation and metastasis of lung adenocarcinoma cells by targeting RRM2.
Cao X, Xue F, Chen H, Shen L, Yuan X, Yu Y Ann Transl Med. 2023; 10(24):1374.
PMID: 36660663 PMC: 9843311. DOI: 10.21037/atm-22-6089.
Hammash D, Mahfood M, Khoder G, Ahmed M, Tlili A, Hamoudi R Breast Cancer (Dove Med Press). 2022; 14:187-198.
PMID: 35936987 PMC: 9354772. DOI: 10.2147/BCTT.S372083.
The Roles of Noncoding RNAs in Systemic Sclerosis.
Liu Y, Cheng L, Zhan H, Li H, Li X, Huang Y Front Immunol. 2022; 13:856036.
PMID: 35464474 PMC: 9024074. DOI: 10.3389/fimmu.2022.856036.